Development of standardized insulin treatment protocols for spontaneous rodent models of type 1 diabetes

Comparative Medicine

Volumn 62, Issue 5, 2012, Pages 381-390

  Grant, Christian W ^a   Duclos, Shane K ^a   Moran Paul, Catherine M ^a   Yahalom, Barak ^a   Tirabassi, Rebecca S ^a   Arreaza Rubin, Guillermo ^b   Spain, Lisa M ^b   Guberski, Dennis L ^a  

^a Biomedical Research Models Inc   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPHANE INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOBREEDING RAT; CLINICAL PROTOCOL; DISEASE MODEL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEEDING; FEMALE; GLYCEMIC CONTROL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; RAT; REST; SINGLE DRUG DOSE; STANDARDIZATION;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLYCEMIC INDEX; INSULIN, ISOPHANE; MICE; MICE, INBRED NOD; RATS; RATS, INBRED BB;

EID: 84870937325     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Anderson MS, Bluestone JA. 2005. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23:447-485. (Pubitemid 40563177)
2. Atkinson MA. 2011. Evaluating preclinical efficacy. Sci Transl Med 3:96cm22.
3. Bizot-Espiard JG, Double A, Guardiola-Lemaitre B, Delagrange P, Ktorza A, Penicaud L. 1998. Diurnal rhythms in plasma glucose, insulin, growth hormone and melatonin levels in fasted and hyperglycaemic rats. Diabetes Metab 24:235-240. (Pubitemid 28289817)
4. Chacra AC, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J; COMPLETE T1D Investigators. 2010. Treatment comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with type 1 diabetes. Diabet Med 27:563-569.
5. Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien YH. 2006. Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci USA 103:12475-12480. (Pubitemid 44267284)
6. Chatenoud L, Primo J, Bach JF. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158:2947-2954. (Pubitemid 127470558)
7. Grossman EJ, Lee DD, Tao J, Wilson RA, Park SY, Bell GI, Chong AS. 2010. Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS ONE 5:e8749.
8. Guberski DL. 1993. Diabetes-prone and diabetes-resistant BB rats: animal models of spontaneous and virally induced diabetes mellitus, lymphocytic thyroiditis, and collagen-induced arthritis. ILAR J 35:29-37.
9. Hillebrands JL, Whalen B, Visser JT, Koning J, Bishop KD, Leif J, Rozing J, Mordes JP, Greiner DL, Rossini AA. 2006. A regulatory CD4+ T cell subset in the BB rat model of autoimmune diabetes expresses neither CD25 nor Foxp3. J Immunol 177:7820-7832. (Pubitemid 44846298)
10. Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press.
11. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598-2608. (Pubitemid 41007846)
12. Kikutani H, Makino S. 1992. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 51:285-322.
13. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, Auchincloss HJ, Flier JS, Strom TB. 2008. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci USA 105:16242-16247.
14. la Fleur SE, Kalsbeek A, Wortel J, Fekkes ML, Buijs RM. 2001. A daily rhythm in glucose tolerance: a role for the suprachiasmatic nucleus. Diabetes 50:1237-1243. (Pubitemid 32500154)
15. Leiter EH. 2005. Nonobese diabetic mice and the genetics of diabetes susceptibility. Curr Diab Rep 5:141-148. (Pubitemid 40823498)
16. Mathews CE. 2005. Utility of murine models for the study of spontaneous autoimmune type 1 diabetes. Pediatr Diabetes 6:165-177. (Pubitemid 41223243)
17. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M. 2010. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160:176-184.
18. Mordes JP, Bortell R, Blankenhorn EP, Rossini AA, Greiner DL. 2004. Rat models of type 1 diabetes: genetics, environment, and autoimmunity. ILAR J 45:278-291.
19. Nakhooda AF, Like AA, Chappel CI, Wei CN, Marliss EB. 1978. The spontaneously diabetic Wistar rat (the "BB" rat): studies prior to and during development of the overt syndrome. Diabetologia 14:199-207. (Pubitemid 8286150)
20. Nelson RW, Henley K, Cole C. 2009. Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats. J Vet Intern Med 23:787-793.
21. Nir T, Melton DA, Dor Y. 2007. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117:2553-2561. (Pubitemid 47494356)
22. Ogawa N, List JF, Habener JF, Maki T. 2004. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53:1700-1705. (Pubitemid 38857027)
23. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ, Atkinson MA. 2009. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 58:2277-2284.
24. Pechhold K, Koczwara K, Zhu X, Harrison VS, Walker G, Lee J, Harlan DM. 2009. Blood glucose levels regulate pancreatic beta-cell proliferation during experimentally-induced and spontaneous autoimmune diabetes in mice. PLoS ONE 4:e4827.
25. Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, Gillis K, Brown L, Lafreniere D, Gallo M, Knox J, Hogeland K, Giannoukakis N. 2008. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 57:1544-1555.
26. Pozzilli P, Signore A, Williams AJ, Beales PE. 1993. NOD mouse colonies around the world - recent facts and figures. Immunol Today 14:193-196. (Pubitemid 23124509)
27. Reddy S, Chai RC, Rodrigues JA, Hsu TH, Robinson E. 2008. Presence of residual beta cells and co-existing islet autoimmunity in the NOD mouse during longstanding diabetes: a combined histochemical and immunohistochemical study. J Mol Histol 39:25-36.
28. Rossini AA, Faustman D, Woda BA, Like AA, Szymanski I, Mordes JP. 1984. Lymphocyte transfusions prevent diabetes in the Bio-Breeding/Worcester rat. J Clin Invest 74:39-46. (Pubitemid 14086042)
29. Ryu S, Kodama S, Ryu K, Schoenfeld DA, Faustman DL. 2001. Reversal of established autoimmune disease by restoration of endogenous beta cell function. J Clin Invest 108:63-72. (Pubitemid 32634923)
30. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. 2007. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148:5136-5144. (Pubitemid 350012634)
31. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT. 2005. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23:115-126. (Pubitemid 41169282)
32. Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, Bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, Xue S, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M, Schatz D, Kaplan B, Von Herrath M, Womer K, Atkinson MA. 2008. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57:405-414.
33. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A. 2008. Combination therapy with glucogon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288.
34. The Jackson Laboratory. [Internet]. T1D incidence studies. Secondary T1D incidence studies. [Cited March 2012]. Available at: http://type1diabetes.jax. org/images/fine-mapping/1976%20cumulative%20inc.jpg.
35. The National Institute of Diabetes and Digestive and Kidney Diseases. [Internet]. 2012. Type 1 diabetes preclinical testing program (T1D-PTP). Secondary type 1 diabetes preclinical testing program (T1D-PTP). [Cited March 2012]. Available at: http://t1diabetes.nih.gov/T1D-PTP.
36. Villanueva DS, Poirier P, Standley PR, Broderick TL. 2003. Prevention of ischemic heart failure by exercise in spontaneously diabetic BB Wor rats subjected to insulin withdrawal. Metabolism 52:791-797. (Pubitemid 36896316)
37. Wang F, Carabino JM, Vergara CM. 2003. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 25:1541-1577, discussion 1539-1540.
38. Whalen BJ, Mordes JP, Rossini AA. 2001. The BB rat as a model of human insulin-dependent diabetes mellitus. Curr Protoc Immunol Chapter 15:Unit 15.3.